Get the Stockscreener App
14.20
0.07%
-0.01
After Hours:
14.20
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $14.20, with a volume of 920.29K.
It is down -0.07% in the last 24 hours and down -3.79% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$14.21
Open:
$14.18
24h Volume:
920.29K
Relative Volume:
0.66
Market Cap:
$11.86B
Revenue:
$3.85B
Net Income/Loss:
$667.93M
P/E Ratio:
21.61
EPS:
0.657
Net Cash Flow:
$142.30M
1W Performance:
-2.14%
1M Performance:
-3.79%
6M Performance:
+9.65%
1Y Performance:
-13.70%
1-Day Range:
$14.09
$14.31
1-Week Range:
$14.09
$14.57
52-Week Range:
$12.26
$16.71
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.20 | 11.83B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
156.40 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.99 | 47.28B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.80 | 43.41B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.38 | 20.69B | 16.70B | -157.13M | 1.19B | -0.155 |
|
NBIX
Neurocrine Biosciences Inc
|
139.60 | 13.78B | 2.41B | 305.80M | 492.20M | 2.95 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Upgrade | HSBC Securities | Hold → Buy |
| Dec-19-24 | Downgrade | Nomura | Buy → Neutral |
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Validea's Top Health Care Stocks Based On Peter Lynch8/25/2025 - Nasdaq
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval - TipRanks
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges - Markets Mojo
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
From Infosys, IndusInd Bank to Natco Pharma, 9 stocks to watch today - financialexpress.com
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Q1 Results Highlights: Infosys net profit rises 9%, Tata Consumer revenue jumps 10% - Moneycontrol
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
Dr. Reddy’s Laboratories Opens Special Window for Share Transfer Requests - TipRanks
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - MSN
Asian ADRs Retreat As Mixed Results Hit The Market - Finimize
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley initiates coverage on Dr. Reddy’s stock with Equalweight rating - Investing.com India
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.34%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):